Selegiline in adults with attention deficit hyperactivity disorder: Clinical efficacy and safety

Psychopharmacology Bulletin

Volumn 32, Issue 3, 1996, Pages 327-334

  Ernst, Monique ^b   Liebenauer, Laura L ^c   Jons, Peter H ^c   Tebeka, Daniel ^c   Cohen, Robert M ^c   Zametkin, Alan J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c NONE

Author keywords

ADHD; adults; MAOI B; placebo; selegiline

Indexed keywords

PLACEBO; SELEGILINE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; MICTURITION DISORDER; MINIMAL BRAIN DYSFUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SLEEP DISORDER; STATISTICAL ANALYSIS; VERTIGO; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DIZZINESS; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 0029858041     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3d ed., revised. Washington, DC: The Association, 1987.
2. Bartko, JJ; Pulver, AE; and Carpenter, WT. The power analysis: Statistical perspectives. Part 2. Psychiatry Res. 23:301-309, 1987.
3. Beck, AT; Ward, CH; and Mendelson, M. An inventory for measuring depression. Arch. Gen. Psychiatry 4:461-471, 1961.
4. Castellanos, FX; Elia, J; Kruesi, MJP; Gulotta, CS; Potter, WZ; Ritchie, GF; Hamburger, SD; and Rapoport, JL. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with Attention-Deficit/Hyperactivity Disorder. Neuropsychopharmacol. 14:125-137, 1996.
5. Conners, CK. A teacher rating scale for use in drug studies with children. Am. J. Psychiatry 126:152-156, 1969.
6. Endicott, J; Spitzer, RL; Fleiss, JL, et al. The Global Assessment Scale: A procedure for overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 33:766-771, 1976.
7. Endicott, J, and Spitzer, RL. A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry 35:837-844, 1978.
8. Guy, W. Subject's Treatment Emergent Symptom Scale. In: Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976. pp. 347-350.
9. Hamilton, M. Development of a rating scale for primary depressive illness. Br. J. Soc. Psychol. 6:278-296, 1967.
10. Jankovic, J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch. Neurol. 50:286-288, 1993.
11. Karoum, F; Chuang, LW; Eisler, T; Calne, DB; Liebowitz, MR; Quitkin, FM; Klein, DF; and Wyatt, RJW. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32:503-509, 1982.
12. Knoll, J. Deprenyl (selegiline): The history of its development and pharmacological action. Acta Neurol. Scand. (Suppl). 95:57-80, 1983.
13. Knoll, J. The pharmacology of selegiline ((-) deprenyl). New aspects. Acta Neurol. Scand. 126:83-91, 1989.
14. National Institute of Mental Health. Special Feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
15. Overall, JE, and Gorham, DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 10:799-812, 1962.
16. Rapoport, JL; Zametkin, AJ; Donnelly, M; and Ismond, D. New trials in attention deficit disorder. Psychopharmacol. Bull. 21:232-235, 1985.
17. Reimherr, FW; Wender, PH; Ebert, MH; and Wood, DR. Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res. 11:71-78, 1984.
18. Reynolds, GP; Riederer, R; Sandler, M; Jellinger, K; and Seemann, D. Amphetamine and 2-phenylethylamine in postmortem parkinsonian brain after (-) deprenyl administration. J. Neural Transm. 43:271-277, 1978.
19. Shaywitz, BA, and Antelman, SM. CSF metabolites in children with minimal brain dysfunction: Evidence for alteration of brain dopamine. J. Pediatr. 90:67-71, 1977.
20. Spencer, T; Wilens, T; Biederman, J; Faraone, SV; Ablon, S; and Lapey, K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch. Gen. Psychiatry 52:434-443, 1995.
21. Sullivan, EA, and Shulman, KI. Diet and monoamine oxidase inhibitors: A re-examination. Can. J. Psychiatry 29:707-711, 1984.
22. Sunderland, T; Mueller, EA; Cohen, RM; Jimerson, DC; Pickar, D; and Murphy, DL. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86:432-437, 1985.
23. Tariot, PN; Sunderland, T; Cohen, RM; Newhouse, PA; Mueller, EA; and Murphy, DL. Tranylcypromine compared with L-deprenyl in alzheimer's disease. J. Clin. Psychopharmacol. 8:23-27, 1988.
24. Wender, PH; Reimherr, FW; and Wood, DR. Attention deficit disorder ("minimal brain dysfunction") in adults. Arch. Gen. Psychiatry 38:449-456, 1981.
25. Wender, PH; Wood, DR; Reimherr, FW; and Ward, M. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res. 9:329-336, 1983.
26. Wender, PH; Wood, DR; Reimherr, FW. Pharmacological treatment of attention deficit disorder, residual type (ADD, RT, "minimal brain dysfunction," "hyperactivity") in adults. Psychopharmacol. Bull. 21:222-231, 1985.
27. Wood, DR; Reimherr, FW; and Wender, PH. The use of L-deprenyl in the treatment of attention deficit disorder, residual type. Psychopharmacol. Bull. 19:627-629, 1983.
28. Zametkin, A; Rapoport, JL; Murphy, DL; Linnoila, M; and Ismond, D. Treatment of hyperactive children with monoamine oxidase inhibitors: Clinical efficacy. Arch. Gen. Psychiatry 42:962-966, 1985.